Acute Kidney Injury Market

Key Highlights:

 

  • The total Acute Kidney Injury market size in the 7MM is USD 5,208 million in 2021 and is projected to grow during the forecast period (2022-2032).
  • The total Mortality-adjusted Incident Cases of AKI in the 7MM comprised of 6,470,038 cases in 2021 and are projected to increase during the forecast period.
  • The total Acute Kidney Injury market size in the United States is expected to increase with a CAGR of 3.7% during the study period (2019–2032).

 

Request a sample to unlock the CAGR for Acute Kidney Injury Market.

 

DelveInsight's "Acute Kidney Injury Market - Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology as well as the AKI market trends in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

AKI market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM AKI market size from 2019 to 2032. The report also covers current AKI treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Acute Kidney Injury Disease Understanding and Treatment Algorithm

Acute Kidney Injury Overview

Acute Kidney Injury is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. Signs and symptoms of AKI includes, nausea, vomiting, weakness, dizziness and, pain in lower back. Some patients are asymptomatic (no noticeable symptoms) and others may have generalized non-specific (not specific to kidneys) symptoms.

 

Acute Kidney Injury Diagnosis

The diagnosis of Acute Kidney Injury is traditionally based on a rise in serum creatinine and/or fall in urine output. The laboratory assessment includes the measurement of Serum Creatinine Level, Urinalysis, renal biopsy and others.

 

Acute Kidney Injury Treatment

The treatment for Acute Kidney Injury depends on the cause of the condition. Most people need to stay in the hospital during treatment and until the recovery of the kidneys. Some possible treatments include temporary hemodialysis, medicines to control the amounts of vitamins and minerals in blood, treatments to keep the right amount of fluid in the blood. There is no approved treatment for AKI, the current treatment practices use conventional therapies (vasopressor, diuretics, statins and others) and renal replacement therapies.

Acute Kidney Injury Epidemiology

The Acute Kidney Injury epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of AKI in Hospitalized Patients, Mortality Adjusted Incident Population of AKI in Hospitalized Patients, Stage-specific Incident Population of AKI and, Age-specific Incident Population of AKI in the 7MM market covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

 

Acute Kidney Injury Key Findings

This section provides glimpse of the AKI epidemiology in the 7MM

 

Acute Kidney Injury Prevalence

 

Country Wise- Acute Kidney Injury Epidemiology

  • The Acute Kidney Injury epidemiology segment also provides the AKI epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The total Mortality-adjusted Incident Cases of AKI in the 7MM comprised of 6,470,038 cases in 2021 and are projected to increase during the forecast period.
  • The total Mortality-adjusted Incident Cases of AKI in the United States is 2,210,647 in 2021. 
  • The US contributed to the largest incident population of AKI, accounting for ~ 34% of the 7MM in 2021.
  • Among the EU-5 countries, Germany accounted for the highest number of AKI cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
  • In Japan, the total mortality-adjusted Incident Cases of AKI was 1,272,824 in 2021 and is anticipated to rise during the forecast period.
  • The stage-specific cases of AKI includes stage I, Stage II and, stage III. Out of which maximum cases were reported in stage I AKI followed by stage II and Stage III.

Acute Kidney Injury Drug Chapters

Drug chapter segment of the AKI report encloses the detailed analysis of AKI emerging (Phase-III and Phase II and Phase I/II) pipeline drugs. It also helps to understand the Acute Kidney Injury clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Acute Kidney Injury Emerging Drugs

 

SB-101: Sentien Biotechnologies

SBI-101 is a combination product that integrates allogeneic Mesenchymal Stromal Cells (MSCs) within an extracorporeal, blood-contacting device. MSCs are a unique source of therapeutic secreted factors that modulate the immune-mediated inflammatory response to acute organ injury. In September 2021, Sentien Biotechnologies partnered with Biomedical Advanced Research and Development Authority (BARDA) to evaluate high dose cohort in Phase I/II trial of SBI-101 for treatment of AKI associated with sepsis.

 

RMC-035 (ROSgard): Guard Therapeutics

RMC-035 is a biological drug candidate (recombinant protein) administered to patients by IV infusion. In the future, it can be used as an in-hospital product for short-term treatment, for example, in connection with heart surgery and kidney transplantation. In April 2022, Guard Therapeutics announced that the Phase II study is called AKITA and is expected to provide blinded interim results by the first quarter of 2023 at topline results during the latter part of 2023.

 

OCE-205: Ocelot Bio

OCE-205’s innovation emanates from its design as a mixed agonist-antagonist peptide selective for the Vasopressin 1a (V1a) receptor with no vasopressin 2 (V2) receptor activity at drug concentrations achieved while treating ESLD. In August 2022, the company announced that the US FDA has granted ODD to its lead candidate OCE-205 for the treatment of hepatorenal syndrome.

 

RBT-1: Renibus Therapeutics

Renibus’ lead product, RBT-1, is a novel pharmacologic intervention combining stannous protoporphyrin and iron sucrose, induces a preconditioning protective effect on the kidney and other organs, upregulating the production of protective proteins to prevent post-operative complications following cardiothoracic surgery, including AKI, days in the ICU, time on ventilator, and hospital readmission rates. Recently, the company announced that an end of Phase II meeting with the FDA would take place in Q3 2022, and Renibus is planning to start a Phase III registration study by Q4 2022.

Note: Detailed emerging therapies assessment will be provided in the final report.

 

Acute Kidney Injury Market

 

Acute Kidney Injury Market Outlook

AKI pipeline with a novel mechanism of action and increasing incidence are major market drivers of AKI market. Additionally, the AKI pipeline is also expected to change the current dynamics of the market, which presently comprises biologics and molecules with new mechanisms of action.

 

Currently, there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of AKI is mainly dominated by the use of Renal Replacement Therapy (RRT) and off-label drugs, which include various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

 

Some patients develop stage 3 AKI and require Renal Replacement Therapy (RRT), and it is indicated for refractory hyperkalemia, volume overload, intractable acidosis, uremic encephalopathy, pericarditis or pleuritis, and removal of certain toxins.

 

The AKI pipeline possessed multiple potential drugs in late- and mid-stage developments to be launched shortly. Key players involved in robust research and development include SB-101: Sentien Biotechnologies, RMC-035 (ROSgard): Guard Therapeutics, OCE-205: Ocelot Bio, RBT-1: Renibus Therapeutics, and others are some of the major players that are going to alter the market dynamics in the coming years.

 

Acute Kidney Injury Key Findings

This section includes a glimpse of the AKI 7MM market.

  • The total Acute Kidney Injury market size in the 7MM is USD 5,208 million in 2021 and is projected to grow during the forecast period (2022-2032).
  • According to the estimates, the highest Acute Kidney Injury market size is from the United States, in 2021 and is anticipated to grow at a CAGR of 3.7%.
  • Among the EU5 countries, Germany has the maximum revenue share in 2021 while Spain has the lowest market share.
  • The Acute Kidney Injury market size in Japan is USD 1,051 million in 2021 which is expected to rise during the forecast period (2022-2032).

 

The United States: Acute Kidney Injury Market Outlook

The total Acute Kidney Injury market size in the United States is expected to increase with a CAGR of 3.7% during the study period (2019–2032).

 

EU-5: Acute Kidney Injury Market Outlook

The total Acute Kidney Injury market size in EU-5 is expected to increase with a CAGR of 0.7% during the study period (2019–2032).

 

Japan: Acute Kidney Injury Market Outlook

The total Acute Kidney Injury market size in Japan is expected to change with a CAGR of -1% during the study period (2019–2032).

 

Acute Kidney Injury Market

 

Analyst Commentary

  • The pipeline of AKI has diverse products targeting prophylaxis of AKI in several complications such as Sepsis, pre and post cardiac-surgery, and HRS-AKI
  • Several biomarkers such as NGAL, Cystatin-C, etc. are being tried and tested to diagnose AKI. Validation of these new biomarkers could provide additional tools to detect the onset and severity of kidney injury
  • Ocelot Bio’s lead asset is OCE-205, is the only drug targeting the patients of Cirrhosis with Ascites, who developed Hepatorenal Syndrome-Acute Kidney Injury
  • reCAP is the only drug in Phase III which is targeting AKI due to sepsis, once it is approved, it might capture a sizable market share because sepsis-AKI has a huge patient pool
  • Currently Exponential Biotherapies  is conducting Phase II trial for EA-230 only in Netherlands based on this we have assumed that the drug will launch first in the EU-5 followed by the US and Japan

Acute Kidney Injury Drugs Uptake

This section focusses on the rate of uptake of the potential drugs expected to get launched in the market during the study period 2019-2032. The analysis covers AKI market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- AM-Pharma’s therapeutic candidate is a proprietary recombinant human Alkaline Phosphatase (recAP) constructed from two naturally occurring human isoforms of the AP enzyme. As per our analysis reCAP, drug uptake in the US is expected to be medium-fast with peak share of 16%, the drug may achieve its highest peak share in 6 years.

Acute Kidney Injury Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for AKI emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professor and Vice Chair Department of Critical Care Medicine and Director, Center for Critical Care Nephrology, PhD, chief executive officer at Renibus , CEO, Guard Therapeutics and others. Their opinion helps to understand and validate current and emerging therapies treatment patterns or AKI market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the AKI market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 5208 million in 2021

Key Companies

Sentien Biotechnologies, Guard Therapeutics, Ocelot Bio, Renibus Therapeutics, Am-Pharma, Alloksys Life Sciences, Exponential Biotherapies

Scope of the Acute Kidney Injury Report

  • The report covers the descriptive overview of Acute Kidney Injury, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Acute Kidney Injury epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for AKI are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of AKI market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM AKI market.

Acute Kidney Injury Report Highlights

  • In the coming years, Acute Kidney Injury market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence AKI R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • As per DelveInsight’s analysis the subtypes- specific of AKI include Stage I, Stage II and Stage III.
  • Expected Launch of potential therapies, SB-101: Sentien Biotechnologies, RMC-035 (ROSgard): Guard Therapeutics, OCE-205: Ocelot Bio, RBT-1: Renibus Therapeutics and others might change the landscape in treatment of AKI.

Acute Kidney Injury Report Insights

  • Acute Kidney Injury Report Insights
  • Acute Kidney Injury Patient Population
  • Acute Kidney Injury Therapeutic Approaches
  • Acute Kidney Injury Pipeline Analysis
  • Acute Kidney Injury Market Size and Trends
  • Acute Kidney Injury Market Opportunities
  • Impact of upcoming Therapies

AKI Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Acute Kidney Injury Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Acute Kidney Injury Market
  • Acute Kidney Injury Drugs Uptake

AKI Report Assessment

  • Current Acute Kidney Injury Treatment Practices
  • Acute Kidney Injury Unmet Needs
  • Acute Kidney Injury Pipeline Product Profiles
  • Acute Kidney Injury Market Attractiveness
  • SWOT
  • Attribute Analysis

Key Questions

Acute Kidney Injury Market Insights:

  • What was the Acute Kidney Injury market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Acute Kidney Injury total market size as well as market size by therapies across the 7MM during the study period (2019–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest AKI market size during the study period (2019–2032)?
  • At what CAGR, the Acute Kidney Injury market is expected to grow at the 7MM level during the study period (2019–2032)?
  • What would be the Acute Kidney Injury market outlook across the 7MM during the study period (2019–2032)?
  • What would be the Acute Kidney Injury market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Acute Kidney Injury Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Acute Kidney Injury?
  • What is the historical AKI patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of AKI at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to AKI?
  • Out of the above-mentioned countries, which country would have the highest incident population of AKI during the study period (2019–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the study period (2019–2032)?

 

Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of AKI? What are the current treatment guidelines for the treatment of AKI in the US and Europe?
  • How many companies are developing therapies for the treatment of AKI?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of AKI?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the AKI therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for AKI and their status?
  • What are the key designations that have been granted for the emerging therapies for AKI?
  • What are the 7MM historical and forecasted market of AKI?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the AKI.
  • To understand the future market competition in the AKI market and Insightful review of the SWOT analysis of AKI.
  • Organize sales and marketing efforts by identifying the best opportunities for AKI in the US, EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for AKI market.
  • To understand the future market competition in the AKI market.

Frequently Asked Questions

What is Acute Kidney Injury?
Acute kidney damage (AKI) occurs when your kidneys abruptly stop functioning normally. It can range from modest renal function loss to total kidney failure. AKI usually occurs as a result of another major illness.
What is the Acute Kidney Injury Market Size in 7MM?
The total Acute Kidney Injury market size was accounted for USD 5,208 Million in the year 2021 and is estimated to grow during the study period (2019-2032).
Who are the leading companies in the Acute Kidney Injury Market Landscape?
The key players in the Acute Kidney Injury market who are in different phases of developing Obesity Therapies are - Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.
What are the Key strengths of the Acute Kidney Injury Market Report?
Key strengths of the Acute Kidney Injury Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers and Market Barriers, and upcoming Acute Kidney Injury market trends.
Which country is expected to account for the most significant prevalent cases for Acute Kidney Injury in the 7MM?
The United States is expected to account for the highest prevalent Acute Kidney Injury cases.

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Swot Analysis

6. Epidemiology And Market Forecast Methodology

7. Acute Kidney Injury (Aki) Market Overview At A Glance In The 7MM

7.1. Market Share (%) Distribution By Therapies In 2019

7.2. Market Share (%) Distribution By Therapies In 2032

8. Disease Background And Overview

8.1. Introduction

8.2. Symptoms

8.3. Types Of Acute Kidney Injury

8.4. Stages Classification

8.5. Risk Factors

8.6. Etiology

8.7. Pathophysiology

8.8. Biomarkers

8.9. Diagnosis

8.9.1. Rifle Criteria

8.9.2. Akin Criteria

8.9.3. Kdigo Criteria

9. Treatment And Prevention

9.1. Acute Renal Failure Or Acute Kidney Injury: United States Based Treatment Guidelines

9.2. European Renal Best Practice (Erbp) Position Statement On The Kidney Disease Improving Global Outcomes (Kdigo) Clinical Practice Guidelines On Acute Kidney Injury

9.3. The Japanese Clinical Practice Guideline For Acute Kidney Injury (2016)

9.4. Nice Guidelines On AKI: Prevention, Detection, And Management (2019)

9.4.1. Assessing Risk Of AKI

9.4.2. Preventing AKI

9.4.3. Detecting AKI

9.4.4. Identifying The Cause Of AKI

9.4.5. Managing Aki

9.4.6. Information And Support For Patients And Carers

10. Epidemiology And Patient Population

10.1. Key Findings

10.2. Assumptions And Rationale

10.2.1. United States

10.2.2. Eu-5

10.2.3. Japan

10.3. Total Incidence Of Acute Kidney Injury (AKI) In Hospitalized Patients In The 7mm

10.4. Total Mortality Adjusted Incident Population Of AKI In Hospitalized Patients In The 7mm

10.5. The United States

10.5.1. Total Incident Population Of AKI In Hospitalized Patients In The US

10.5.2. Mortality Adjusted Incident Population Of AKI In Hospitalized Patients In The US

10.5.3. Stage-Specific Incident Population Of AKI In The US

10.5.4. Age-Specific Incident Population Of AKI In The US

10.6. EU-5

10.6.1. Total Incident Population Of AKI In Hospitalized Patients In The EU-5

10.6.2. Mortality Adjusted Incident Population Of AKI In Hospitalized Patients In The EU-5

10.6.3. Stage-Specific Incident Population Of AKI In The EU-5

10.6.4. Age-Specific Incident Population Of AKI In The EU-5

10.7. Japan

10.7.1. Total Incident Population Of AKI In Hospitalized Patients In Japan

10.7.2. Mortality Adjusted Incidence Of AKI In Hospitalized Patients In Japan

10.7.3. Stage-Specific Incident Population Of AKI In Japan

10.7.4. Age-Specific Incidence Of AKI In Japan

11. Organizations Contributing Towards Acute Kidney Injury

12. Patient Journey

13. Key Endpoints In AKI

14. Emerging Drugs

14.1. Key Cross

14.2. SB-101: Sentien Biotechnologies

14.2.1. Product Description

14.2.2. Other Developmental Activity

14.2.3. Clinical Developmental

14.2.4. Safety And Efficacy

14.3. RMC-035 (Rosgard): Guard Therapeutics

14.3.1. Product Description

14.3.2. Other Developmental Activity

14.3.3. Clinical Development

14.3.4. Safety And Efficacy

14.4. OCE-205: Ocelot Bio

14.4.1. Product Description

14.4.2. Other Developmental Activities

14.4.3. Clinical Development

14.5. RBT-1: Renibus Therapeutics

14.5.1. Product Description

14.5.2. Clinical Development

14.5.3. Safety And Efficacy

14.6. Ilofotase Alfa: Am-Pharma

14.6.1. Product Description

14.6.2. Other Developmental Activities

14.6.3. Clinical Development

14.6.4. Safety And Efficacy

14.7. Brescap: Alloksys Life Sciences

14.7.1. Product Description

14.7.2. Clinical Development

14.8. EA-230: Exponential Biotherapies

14.8.1. Product Description

14.8.2. Clinical Development

14.8.3. Safety And Efficacy

15. Acute Kidney Injury (AKI): 7MM Market Analysis

15.1. Key Findings

15.2. Market Outlook

15.3. Key Market Forecast Assumptions

15.4. Total Market Size Of AKI In The 7mm

15.5. Total Market Size Of AKI By Therapies In The 7mm

15.6. United States Market Size

15.6.1. Total Market Size Of AKI In The US

15.6.2. Market Size Of AKI By Therapies In The US

15.7. EU-5 Market Size

15.7.1. Total Market Size Of AKI In The EU-5

15.7.2. Market Size Of AKI By Therapies In The EU-5

15.8. Japan

15.8.1. Total Market Size Of AKI In Japan

15.8.2. Market Size Of AKI By Therapies In Japan

16. Kol Views

17. Unmet Needs

18. Market Access And Reimbursement

18.1. Centers Of Medicare And Medicaid Services (US)

18.2. American Kidney Fund (AKF)

18.3. Reimbursement And Cost Of Acute Kidney Injury In Europe

18.3.1. United Kingdom (England)

18.3.2. France

18.3.3. Germany

18.3.4. Italy

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. Delveinsight Capabilities

21. Disclaimer

22. About Delveinsight

List of Table

Table 1: Summary of Acute Kidney Injury Market, and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) classification

Table 4: KDIGO Criteria

Table 5: Causes of AKI: Exposures and Susceptibilities for non-specific AKI

Table 6: Biomarkers of AKI

Table 7: RIFLE Criteria for ARF

Table 8: AKIN Criteria for ARF

Table 9: KDIGO Criteria for AKI

Table 10: Renal Replacement Therapy (RRT) Modalities for ARF

Table 11: Total Incident Population of AKI in Hospitalized Patients in the 7MM (2019–2032)

Table 12: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the 7MM (2019–2032)

Table 13: Total Incident Population of AKI in Hospitalized Patients in the US (2019–2032)

Table 14: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the US (2019–2032)

Table 15: Stage-specific Incident Population of AKI in the US, in Thousand (2019–2032)

Table 16: Age-specific Incident Population of AKI in the US (2019–2032)

Table 17: Total Incidence of AKI in Hospitalized Patients in the EU-5 in Thousands (2019–2032)

Table 18: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the EU-5 (2019–2032)

Table 19: Stage-specific Incident Population of AKI in the EU-5 (2019–2032)

Table 20: Age-specific Incident Population of AKI in the EU-5 (2019–2032)

Table 21: Total Incident Population of AKI in Hospitalized Patients in Japan, in Thousand (2019–2032)

Table 22: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in Japan (2019–2032)

Table 23: Stage-specific Incident Population of AKI in Hospitalized Patients in Japan (2019–2032)

Table 24: Age-specific Incident Population of AKI in Japan (2019–2032)

Table 25: Organizations contributing toward Acute Kidney Injury (AKI)

Table 26: Comparison of emerging drugs for AKI

Table 27: SB-101, Clinical Trial Description, 2022

Table 28: RMC-035, Clinical Trial Description, 2022

Table 29: OCE-205 Clinical Trial Description, 2022

Table 30: RBT-1 Clinical Trial Description, 2022

Table 31: recAP, Clinical Trial Description, 2022

Table 32: bRESCAP, Clinical Trial Description, 2022

Table 33: EA-230, Clinical Trial Description, 2022

Table 34: Key Market Forecast Assumptions for recAP

Table 35: Key Market Forecast Assumptions for RMC--035

Table 36: Key Market Forecast Assumptions for bRESCAP

Table 37: Key Market Forecast Assumptions for EA-230

Table 38: Key Market Forecast Assumptions for RBT-1

Table 39: Key Market Forecast Assumptions for OCE-205

Table 40: Market Size of AKI in the 7MM in USD million (2019–2032)

Table 41: Market Size of AKI by therapies in the 7MM, in USD million (2019–2032)

Table 42: Market Size of AKI in the US, USD million (2019–2032)

Table 43: Market Size of AKI by therapies in the US, in USD million (2019–2032)

Table 44: Market Size of AKI in the EU-5, in USD million (2019–2032)

Table 45: Market Size of AKI by therapies in EU5, in USD million (2019–2032)

Table 46: Market Size of AKI in Japan, in USD million (2019–2032)

Table 47: Market Size of AKI by therapies in Japan, in USD million (2019–2032)

List of Figures

Figure 1: Types of Acute Kidney Injury

Figure 2: Risk factors associated with Acute Kidney Injury

Figure 3: Common Causes of Acute Kidney Injury

Figure 4: Pathophysiology of Acute Kidney Injury

Figure 5: Biomarkers of Acute Kidney Injury

Figure 6: Stage-based management of Acute Kidney Injury

Figure 7: Total Incident Population of AKI in Hospitalized Patients in the 7MM (2019–2032)

Figure 8: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the 7MM (2019–2032)

Figure 9: Total Incident Population of AKI in Hospitalized Patients in the US (2019–2032)

Figure 10: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the US (2019–2032)

Figure 11: Stage-specific Incident Population of AKI in the US (2019–2032)

Figure 12: Age-specific Incident Population of AKI in the US (2019–2032)

Figure 13: Total Incident Population of AKI in Hospitalized Patients in the EU-5 (2019–2032)

Figure 14: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the EU-5 (2019–2032)

Figure 15: Stage-specific Incident Population of AKI the EU-5 (2019–2032)

Figure 16: Age-specific Incident Population of AKI in the EU-5 (2019–2032)

Figure 17: Total Incident Population of AKI in Hospitalized Patients in Japan (2019–2032)

Figure 18: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in Japan (2019–2032)

Figure 19: Stage-specific Incident Population of AKI in Japan (2019–2032)

Figure 20: Age-specific Incident Population of AKI in Japan (2019–2032)

Figure 21: Market Size of AKI in the 7MM in USD million (2019–2032)

Figure 22: Market Size of AKI by Therapies in the 7MM, in USD million (2019–2032)

Figure 23: Market Size of AKI in the US, USD million (2019–2032)

Figure 24: Market Size of AKI by therapies in the US, in USD million (2019–2032)

Figure 25: Market Size of AKI in the EU-5, USD million (2019–2032)

Figure 26: Market Size of AKI by Therapies in the EU-5, in USD million (2019–2032)

Figure 27: Market Size of AKI in Japan, USD million (2019–2032)

Figure 28: Market Size of AKI by Therapies in Japan, in USD million (2019–2032)

SENTIEN BIOTECHNOLOGIES
GUARD THERAPEUTICS
OCELOT BIO
RENIBUS THERAPEUTICS
AM-PHARMA
ALLOKSYS LIFE SCIENCES
EXPONENTIAL BIOTHERAPIES

 

Forward to Friend

Need A Quote